Phase 3 Readout
ASND: Phase 3 Topline: A Phase 3, Multicenter, Randomized, Open-Label Trial Investigating the Safety, Tolerability and Effi
June 1, 2028. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- June 1, 2028
- Company
- Ascendis Pharma A/S (ASND)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Phase 3, Multicenter, Randomized, Open-Label Trial Investigating the Safety, Tolerability and Effi
- Company
- Ascendis Pharma A/S (ASND)
- Indication
- Hypoparathyroidism; Parathyroid Diseases; Endocrine System Diseases